H.C. Wainwright lowered the firm’s price target on Plus Therapeutics (PSTV) to $5.50 from $8 and keeps a Buy rating on the shares. The firm cites the increased number of outstanding shares and warrants associated with the company’s latest placement for the target cut.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Reports 2024 Financial Results and Progress
- Plus Therapeutics announces FDA conditionally accepted name REYOBIQ
- Plus Therapeutics initiated with a Buy at D. Boral Capital
- Biotech Alert: Searches spiking for these stocks today
- Plus regains compliance with Nasdaq minimum stockholders’ equity requirement